The Company
Alpha Cognition utilizes a portfolio approach to identify, validate, and develop bioactives for neuroprotection and the early treatment of neurological diseases. Alpha Cognition identifies bioactive compounds within historically-proven natural treatments with the goal of validating therapeutic candidates and ultimately developing treatments for Parkinson’s, Alzheimer’s, ALS and chronic nerve pain.
The Partnership
Impactreneur is an early stage equity investor in Alpha Cognition.
View our other investments
